US FDA approves Wyeth's Premarin for postmenopausal dyspareunia
This article was originally published in Scrip
Executive Summary
The US FDA has approved a low-dose oestrogen vaginal cream 0.5g version of Wyeth's Premarin (conjugated oestrogens) for the treatment of moderate to severe postmenopausal dyspareunia (painful sexual intercourse), making it the first vaginal oestrogen therapy for this indication.